The potential significance of high avidity immunoglobulin G (IgG) for protective immunity towards SARS-CoV-2
- PMID: 33713819
- PMCID: PMC7944804
- DOI: 10.1016/j.ijid.2021.01.061
The potential significance of high avidity immunoglobulin G (IgG) for protective immunity towards SARS-CoV-2
Abstract
Avidity is defined as the strength of binding between immunoglobulin G (IgG) and its specific target epitope. IgG of high avidity is established during affinity maturation. Failure to achieve high avidity IgG may result in a lack of protective immunity towards infection and disease. It is known that the interaction between SARS-CoV-2 spike protein and its cellular receptor is driven by high affinity. Therefore, it is predictable that protective antibodies towards SARS-CoV-2 should show high affinity/avidity. AVIDITY AFTER SARS-COV-2 INFECTION: Recent findings by several groups demonstrate that the serological response towards infection with SARS-CoV-2 and seasonal coronaviruses is characterized by incomplete avidity maturation, followed by a decline of the serological response. This response might facilitate reinfection, prevent herd immunity and potentially allow repeated cycles of infection. CONSEQUENCES FOR VACCINATION TOWARDS SARS-COV-2: Therefore, the sole focus on antibody titers reached after vaccination towards SARS-CoV-2 might not be sufficient to evaluate the degree of achieved protection. Rather, it is suggested to include avidity determination to optimize vaccination protocols and achieve high avidity IgG directed towards SARS-CoV-2 through vaccination. Avidity determination might also be useful to control for truly protective immunity towards SARS-CoV-2 in individual cases.
Keywords: Avidity; Covid-19; Neutralizing antibody; Protective immunity; SARS-CoV-2; Vaccination.
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Similar articles
-
Vaccination versus infection with SARS-CoV-2: Establishment of a high avidity IgG response versus incomplete avidity maturation.J Med Virol. 2021 Dec;93(12):6765-6777. doi: 10.1002/jmv.27270. Epub 2021 Aug 20. J Med Virol. 2021. PMID: 34387884 Free PMC article.
-
Incomplete IgG avidity maturation after seasonal coronavirus infections.J Med Virol. 2022 Jan;94(1):186-196. doi: 10.1002/jmv.27291. Epub 2021 Aug 27. J Med Virol. 2022. PMID: 34427932
-
Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.J Immunol Res. 2022 Aug 31;2022:4813199. doi: 10.1155/2022/4813199. eCollection 2022. J Immunol Res. 2022. PMID: 36093434 Free PMC article.
-
Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity.Biochem Biophys Res Commun. 2021 Jan 29;538:187-191. doi: 10.1016/j.bbrc.2020.10.108. Epub 2020 Nov 7. Biochem Biophys Res Commun. 2021. PMID: 33187644 Free PMC article. Review.
-
Immune response following infection with SARS-CoV-2 and other coronaviruses: A rapid review.Rev Med Virol. 2021 Mar;31(2):e2162. doi: 10.1002/rmv.2162. Epub 2020 Sep 23. Rev Med Virol. 2021. PMID: 32964627 Free PMC article. Review.
Cited by
-
Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection.J Taibah Univ Med Sci. 2023 Jun;18(3):600-638. doi: 10.1016/j.jtumed.2022.11.007. Epub 2022 Dec 17. J Taibah Univ Med Sci. 2023. PMID: 36570799 Free PMC article. Review.
-
Kinetics of the SARS-CoV-2 Antibody Avidity Response Following Infection and Vaccination.Viruses. 2022 Jul 8;14(7):1491. doi: 10.3390/v14071491. Viruses. 2022. PMID: 35891471 Free PMC article.
-
Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice.Mil Med Res. 2021 Aug 31;8(1):47. doi: 10.1186/s40779-021-00342-3. Mil Med Res. 2021. PMID: 34465396 Free PMC article. Review.
-
Unmethylated CpG motif-containing genomic DNA fragments of bacillus calmette-guerin improves immune response towards a DNA vaccine for COVID-19.Vaccine. 2021 Oct 1;39(41):6050-6056. doi: 10.1016/j.vaccine.2021.08.103. Epub 2021 Sep 3. Vaccine. 2021. PMID: 34521552 Free PMC article.
-
Evidence of SARS-CoV-2 symptomatic reinfection in four healthcare professionals from the same hospital despite the presence of antibodies.Int J Infect Dis. 2022 Apr;117:146-154. doi: 10.1016/j.ijid.2022.01.006. Epub 2022 Jan 10. Int J Infect Dis. 2022. PMID: 35017107 Free PMC article.
References
-
- Bauer G., Struck F., Schreiner P., Staschik E., Soutschek E., Motz M. The challenge of avidity determination in SARS-CoV-2 serology. J Med Virol. 2021;93:3092–3104. doi: 10.1002/jmv.26863. under revision. Preprint deposited at the server of the World Health Organization, 2021 a. - DOI - PMC - PubMed
-
- Bauer G., Struck F., Schreiner P., Staschik E., Soutschek E., Motz M. The serological response to SARS corona virus-2 is characterized by frequent incomplete maturation of functional affinity (avidity) Sci Rep. 2021 doi: 10.21203/rs.3.rs-104847/v1. under review, Preprint available at Research Square, b. - DOI
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous